Tumours

Current Orthopaedics

Volumn 14, Issue 2, 2000, Pages 117-132

  Choong, P F M ^a   Sim, F H ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

BONE TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SARCOMA;

EID: 0034092371     PISSN: 02680890     EISSN: None     Source Type: Journal    
DOI: 10.1054/cuor.1999.0070     Document Type: Review

References (117)

1. Berquist T. H. Magnetic resonance imaging of primary skeletal neoplasms. Radiol Clin North Am. 31:1993;411-424.
2. Ma L. D. Magnetic resonance imaging of musculoskeletal tumors: skeletal and soft tissue masses. Curr Probl Diagn Radiol. 28:1999;29-62.
3. Erlemann R., Reiser M. F., Peters P. E. Musculoskeletal neoplasms: static and dynamic Gd-DTPA - enhanced MR imaging. Radiology. 171:1989;767-773.
4. Heiserman J. E. MR angiography. Toward faster and more accurate methods. Neuroimaging Clin N Am. 9:1999;253-261.
5. Kransdorf M. J., Jelinek J. S., Moser R. P. Jr. Imaging of soft tissue tumors. Radiol Clin North Am. 31:1993;359-372.
6. Ko S. F., Wan Y. L., Lee T. Y., Ng S. H., Lin J. W., Chen W. J. CT features of calcifications in abdominal malignant fibrous histiocytoma. Clin Imaging. 22:1998;408-413.
7. Yamaguchi T., Dorfman H. D. Radiographic and histologic patterns of calcification in chondromyxoid fibroma. Skeletal Radiol. 27:1998;559-564.
8. Hicks R. Nuclear medicine techniques provide unique physiologic characterisation of suspected and known soft tissue and bone sarcomas. Acta Orthop Scand. 68:1997;25-36.
9. Kobayashi Y., Ozaki T., Takeda Y., Kawai A., Inoue H. Evaluation of the effect of preoperative chemotherapy in bone sarcomas. 99mTc-HMDP scintigraphy in 34 cases. Acta Orthop Scand. 69:1998;611-616.
10. Ozcan Z., Burak Z., Kumanlioglu K. Assessment of chemotherapy-induced changes in bone sarcomas: clinical experience with 99Tcm-MDP three-phase dynamic bone scintigraphy. Nucl Med Commun. 20:1999;41-48.
11. Sehweil A. M., McKillop J. H., Milroy R., Wilson R., Abdel-Dayem H. M., Omar Y. T. Mechanism of 201Tl uptake in tumours. Eur J Nucl Med. 15:1989;376-379.
12. Ohtomo K., Terui S., Yokoyama R. Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma. J Nucl Med. 37:1996;1444-1448.
13. Sato O., Kawai A., Ozaki T., Kunisada T., Danura T., Inoue H. Value of thallium-201 scintigraphy in bone and soft tissue tumors. J Orthop Sci. 3:1998;297-303.
14. Kole A. C., Nieweg O. E., van Ginkel R. J. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann Surg Oncol. 4:1997;57-63.
15. Eary J. F., Conrad E. U., Bruckner J. D. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res. 4:1998;1215-1220.
16. Eary J. F., Mankoff D. A. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med. 39:1998;250-254.
17. Miraldi F., Adler L. P., Faulhaber P. PET imaging in soft tissue sarcomas. Cancer Treat Res. 91:1997;51-64.
18. Yamamoto T., Seino Y., Fukumoto H. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 170:1990;223-230.
19. Kubota R., Kubota K., Yamada S., Tada M., Ido T., Tamahashi N. Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. J Nucl Med. 35:1994;1067-1075.
20. Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell. 70:1992;523-526.
21. Leach F. S., Tokino T., Meltzer P. p53 Mutation and Mdm2 amplification in human soft tissue sarcomas. Cancer Res. 53:1993;2231-2234.
22. Araki N., Uchida A., Kimura T. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop. 1991;271-277.
23. Choong P. F., Rydholm A., Mertens F., Mandahl N. Musculoskeletal oncology - advances in cytogenetics and molecular genetics and their clinical implications. Acta Oncol. 36:1997;245-254.
24. Turc-Carel C., Aurias A., Mugneret F. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11; 22)(q24; q12). Cancer Genet Cytogenet. 32:1988;229-238.
25. Limon J., Mrozek K., Mandahl N. Cytogenetics of synovial sarcoma: presentation of ten new cases and review of the literature. Genes Chromosomes Cancer. 3:1991;338-345.
26. Sreekantaiah C., Karakousis C. P., Leong S. P., Sandberg A. A. Cytogenetic findings in liposarcoma correlate with histopathologic subtypes. Cancer. 69:1992;2484-2495.
27. Choong P. F., Mandahl N., Mertens F. 19p+ marker chromosome correlates with relapse in malignant fibrous histiocytoma. Genes Chromosomes Cancer. 16:1996;88-93.
28. Nilsson G., Skytting B., Xie Y. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res. 59:1999;3180-3184.
29. Harvei S., Solheim O. The prognosis in osteosarcoma: Norwegian National Data. Cancer. 48:1981;1719-1723.
30. Falk S., Alpert M. Five-year survival of patients with Ewing's sarcoma. Surg Gynecol Obstet. 124:1967;319-324.
31. Saeter G., Bruland O. S., Folleras G., Boysen M., Hoie J. Extremity and non-extremity high-grade osteosarcoma - the Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol. 8:1996;129-134.
32. Nesbit M. E. Jr, Gehan E. A., Burgert E. O. Jr. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 8:1990;1664-1674.
33. Rosen G., Caparros B., Huvos A. G. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 49:1982;1221-1230.
34. Meyers P. A., Heller G., Healey J. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 10:1992;5-15.
35. Smith M. A., Ungerleider R. S., Horowitz M. E., Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 83:1991;1460-1470.
36. Ferrari S., Sassoli V., Orlandi M. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother. 5:1993;135-141.
37. Kusuzaki K., Hirata M., Takeshita H. Relationship between P-glycoprotein positivity, doxorubicin binding ability and histologic response to chemotherapy in osteosarcomas. Cancer Lett. 138:1999;203-208.
38. Guo W., Healey J. H., Meyers P. A. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 5:1999;621-627.
39. Bruland O. S., Skretting A., Solheim O. P., Aas M. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncol. 35:1996;381-384.
40. Strander H., Einhorn S. Interferons and the tumor cell. Biotherapy. 8:1996;213-218.
41. Kleinerman E. S. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 9:1995;927-938.
42. Bacci G., Picci P., Mercuri M. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma. Acta Oncol. 37:1998;671-676.
43. Ferrari S., Mercuri M., Rosito P. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. J Chemother. 10:1998;484-491.
44. Demetri G. D. High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Semin Oncol. 23:1996;22-26.
45. Bramwell V., Rouesse J., Steward W. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 12:1994;1137-1149.
46. Chang A. E., Kinsella T., Glatstein E. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol. 6:1988;1491-1500.
47. Eilber F. R., Giuliano A. E., Huth J. F., Morton D. L. A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma. Am J Clin Oncol. 11:1988;39-45.
48. Mazanet R., Antman K. H. Adjuvant therapy for sarcomas. Semin Oncol. 18:1991;603-612.
49. Alvegard T. A., Sigurdsson H., Mouridsen H. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 7:1989;1504-1513.
50. Mertens W., Bramwell V. Adjuvant chemotherapy for soft tissue sarcomas. Haematology/Oncology Clin North Am. 9:1995;801-816.
51. Zalupski M., Baker L. Systemic adjuvant chemotherapy for soft tissue sarcomas. Haematology/Oncology CLin North Am. 9:1995;787-800.
52. Demetri G., Elias A. Results of single agent and combination chemotherapy for advanced soft tissue sarcomas. Haematology/Oncology Clin North Am. 9:1995;765-786.
53. Antman K. H. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 24:1997;556-560.
54. Lancet. 350:1997;1647-1654.
55. Tierney J. F., Mosseri V., Stewart L. A., Souhami R. L., Parmar M. K. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer. 72:1995;469-475.
56. Choong P. F., Akerman M., Willen H. Prognostic value of Ki-67 expression in 182 soft tissue sarcomas. Proliferation - a marker of metastasis? Apmis. 102:1994;915-924.
57. Choong P. F., Akerman M., Willen H. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? Apmis. 103:1995;797-805.
58. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl. 259:1994;1-31.
59. Choong P. F., Ferno M., Akerman M. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer. 69:1996;268-272.
60. Kilpatrick S. E., Doyon J., Choong P. F., Sim F. H., Nascimento A. G. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer. 77:1996;1450-1458.
61. Jablons D., Steinberg S. M., Roth J., Pittaluga S., Rosenberg S. A., Pass H. I. Metastasectomy for soft tissue sarcoma. Further evidence for efficacy and prognostic indicators. J Thorac Cardiovasc Surg. 97:1989;695-705.
62. Choong P. F., Pritchard D. J., Rock M. G., Sim F. H., Frassica F. J. Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. Acta Orthop Scand. 66:1995;561-568.
63. Gadd M. A., Casper E. S., Woodruff J. M., McCormack P. M., Brennan M. F. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 218:1993;705-712.
64. Alvegard T., Saeter G. THe role of pulmonary metastasectomy for soft tissue sarcoma. Acta Orthop Scand. 68:1997;145-147.
65. Harrison L. B., Franzese F., Gaynor J. J., Brennan M. F. Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys. 27:1993;259-265.
66. O'Connor M., Pritchard D. J., Gunderson L. L. Integration of limb-sparing surgery, brachytherapy, and external-beam irradiation in the treatment of soft-tissue sarcomas. Clin Orthop. 289:1993;73-80.
67. Suit H., Spiro I. Radiation as a therapeutic modality in sarcomas of the soft tissue. Hematol Oncol Clin North Am. 9:1995;733-746.
68. Alekhteyar K. M., Leung D. H., Brennan M. F., Harrison L. B. The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margin. Int J Radiat Oncol Biol Phys. 36:1996;321-324.
69. Pisters P. W., Harrison L. B., Leung D. H., Woodruff J. M., Casper E. S., Brennan M. F. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 14:1996;859-868.
70. Epstein A. H., Lebovics R. S., Van Waes C., Smith J., Okunieff P., Cook J. A. Intravenous delivery of 5′-iododeoxyuridine during hyperfractionated radiotherapy for locally advanced head and neck cancers: results of a pilot study. Laryngoscope. 108:1998;1090-1094.
71. Sondak V. K., Robertson J. M., Sussman J. J., Saran P. A., Chang A. E., Lawrence T. S. Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with five-year follow-up. Ann Surg Oncol. 5:1998;106-112.
72. Goffman T., Tochner Z., Glatstein E. Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation. Cancer. 67:1991;572-576.
73. Enneking W., Spanier S., Goodman M. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop. 153:1980;106-120.
74. Sim F. H., Frassica F. J., Chao E. Y. Orthopaedic management using new devices and prostheses. Clin Orthop. 312:1995;160-172.
75. Capanna R., Morris H. G., Campanacci D., Del Ben M., Campanacci M. Modular uncemented prosthetic reconstruction after resection of tumours of the distal femur. J Bone Joint Surg Br. 76:1994;178-186.
76. Choong P. F., Sim F. H., Pritchard D. J., Rock M. G., Chao E. Y. Megaprostheses after resection of distal femoral tumors. A rotating hinge design in 30 patients followed for 2-7 years. Acta Orthop Scand. 67:1996;345-351.
77. O'Connor M., Sim F. H., Chao E. Y. Limb salvage for neoplasms of the shoulder girdle. Intermediate reconstructive and functional results. J Bone Joint Surg Am. 78:1996;1872-1888.
78. Morris H. G., Capanna R., Del Ben M., Campanacci D. Prosthetic reconstruction of the proximal femur after resection for bone tumors. J Arthroplasty. 10:1995;293-299.
79. Gottsauner-Wolf F., Egger E. L., Schultz F. M., Sim F. H., Chao E. Y. Tendons attached to prostheses by tendon-bone block fixation: an experimental study in dogs. J Orthop Res. 12:1994;814-821.
80. Gottsauner-Wolf F., Egger E. L., Markel M. D., Schultz F. M., Chao E. Y. Fixation of canine tendons to metal. Acta Orthop Scand. 65:1994;179-184.
81. Gottsauner-Wolf F., Egger E., Giurea A. Biologic attachment of an allograft bone and tendon transplant to titanium prosthesis. Clin Orthop. 358:1999;101-110.
82. Damron T., Sim F., Shives T., An K., Rock M., Pritchard D. Intercalary spacers in the treatment of segmentally destructive diaphyseal humeral lesions in disseminated malignancies. Clin Orthop. 324:1996;233-243.
83. Okada Y., Suka T., Sim F. H., Gorski J. P., Chao E. Y. Comparison of replacement prostheses for segmental defects of bone. Different porous coatings for extracortical fixation. J Bone Joint Surg [Am]. 70:1988;160-172.
84. Virolainen P., Inoue N., Nagao M., Ohnishi I., Frassica F., Chao E. Autogenous onlay grafting for enhancement of extracortical tissue formation over porous coated segmental replacement prostheses. J Bone Joint Surg Am. 81:1999;493-499.
85. Shin D., Choong P. F.M., Chao E. Y.S., Sim F. H. 10-20 year follow-up in 31 patients with large tumour endoprostheses and extracortical bone bridging. Acta Orthop Scand. 1999.
86. Onsten I., Nordqvist A., Carlsson A. S., Besjakov J., Shott S. Hydroxyapatite augmentation of the porous coating improves fixation of tibial components. A randomised RSA study in 116 patients. J Bone Joint Surg Br. 80:1998;417-425.
87. Capello W. N., JA D. A., Feinberg J. R., Manley M. T. Hydroxyapatite-coated total hip femoral components in patients less than fifty years old. Clinical and radiographic results after five to eight years of follow-up. J Bone Joint Surg Am. 79:1997;1023-1029.
88. Choong P. F. The role of allografts in tumour surgery. Acta Orthop Scand Suppl. 273:1997;89-94.
89. Wunder J., Davis A., Hummel J., Mandelcorn J., Griffin A., Bell R. The effect of intramedullary cement on intercalary allograft reconstruction of bone defects after tumour resection: a pilot study. Can J Surg. 38:1995;521-527.
90. Hejna M. J., Gitelis S. Allograft prosthetic composite replacement for bone tumors. Semin Surg Oncol. 13:1997;18-24.
91. Hornicek F. J. Jr, Mnaymneh W., Lackman R. D., Exner G. U., Malinin T. I. Limb salvage with osteoarticular allografts after resection of proximal tibia bone tumors. Clin Orthop. 352:1998;179-186.
92. Lord C., Gebhardt M., Tomford W., Mankin H. The incidence, nature and treatment of allograft infections. J Bone Joint Surg. 70:1988;369-376.
93. Kumta S., Yip K., Roy N., Lee S., Leung P. Revascularisation of bone allografts following vascular bundle implantation: an experimental study in rats. Arch Orthop Trauma Surg. 115:1996;206-210.
94. Hofmann G. O., Kirschner M. H., Wagner F. D., Brauns L., Gonschorek O., Buhren V. Allogeneic vascularized transplantation of human femoral diaphyses and total knee joints-first clinical experiences. Transplant Proc. 30:1998;2754-2761.
95. Rostek M., Morrison W. A. Microsurgery - its role in soft tissue and bone tumour reconstruction. Acta Orthop Scand Suppl. 273:1997;95-100.
96. Ozaki T., Hillmann A., Wuisman P., Winkelmann W. Reconstruction of tibia by ipsilateral vascularized fibula and allograft. 12 cases with malignant bone tumors. Acta Orthop Scand. 68:1997;298-301.
97. Ihara K., Shigetomi M., Kawai S., Doi K., Yamamoto M. Functioning muscle transplantation after wide excision of sarcomas in the extremity. Clin Orthop. 1999;140-148.
98. Morrison W., Penington A., Kumta S., Callan P. Clinical applications and technical limitations of prefabricated flaps. Plast Reconstr Surg. 99:1997;378-385.
99. Hickey M., Wilson Y., Hurley J., Morrison W. Mode of vascularisation of control and basic fibroblast growth factor-stimulated prefabricated skin flaps. Plast Reconstr Surg. 101:1998;1296-1304.
100. Maitz P., Pribaz J., Hergrueter C. Impact of tissue expansion on flap prefabrication: an experimental study in rabbits. Microsurgery. 17:1996;35-40.
101. Ono I., Gunji H., Suda K. Bone induction of hydroxyapatite combined with bone morphogenetic protein and covered with periosteum. Plast Reconstr Surg. 95:1995;1265-1272.
102. Kusumoto K., Bessho K., Fujimara K., Akioka J., Ogawa Y., Iizuka T. Prefabricated muscle flap including bone induced by recombinant human bone morphogenetic protein-2: an experimental study of ectopic osteoinduction in a rat latissimus dorsi muscle flap. Br J Plast Surg. 51:1998;275-280.
103. Ward W. G., Yang R. S., Eckardt J. J. Endoprosthetic bone reconstruction following malignant tumor resection in skeletally immature patients. Orthop Clin North Am. 27:1996;493-502.
104. Cool W. P., Carter S. R., Grimer R. J., Tillman R. M., Walker P. S. Growth after extendible endoprosthetic replacement of the distal femur. J Bone Joint Surg Br. 79:1997;938-942.
105. Verkerke G. J., Schraffordt Koops H., Veth R. P., van Horn J. R., Postma L., Grootenboer H. J. First clinical experience with a noninvasively extendable endoprosthesis: a limb-saving procedure in children suffering from a malignant bone tumor. Artif Organs. 21:1997;413-417.
106. Delepine G., Delepine N., Desbois J. C., Goutallier D. Expanding prostheses in conservative surgery for lower limb sarcoma. Int Orthop. 22:1998;27-31.
107. Tillman R. M., Grimer R. J., Carter S. R., Cool W. P., Sneath R. S. Growing endoprostheses for primary malignant bone tumors. Semin Surg Oncol. 13:1997;41-48.
108. Schindler O. S., Cannon S. R., Briggs T. W., Blunn G. W. Stanmore custom-made extendible distal femoral replacements. Clinical experience in children with primary malignant bone tumours [published erratum appears in J Bone Joint Surg Br 1998 May; 80(3):562]. J Bone Joint Surg Br. 79:1997;927-937.
109. Donnan L., Saleh M. Monolateral fixators in paediatric limb reconstruction. Current Orthopaedics. 12:1998;159-166.
110. Canadell J., Forriol F., Cara J. A. Removal of metaphyseal bone tumours with preservation of the epiphysis. Physeal distraction before excision. J Bone Joint Surg Br. 76:1994;127-132.
111. Teixeira J. O., Urist M. R. Bone morphogenetic protein induced repair of compartmentalized segmental diaphyseal defects. Arch Orthop Trauma Surg. 117:1998;27-34.
112. Zellin G., Linde A. Treatment of segmental defects in long bones using osteopromotive membranes and recombinant human bone morphogenetic protein-2. An experimental study in rabbits. Scand J Plast Reconstr Surg Hand Surg. 31:1997;97-104.
113. Zegzula H. D., Buck D. C., Brekke J., Wozney J. M., Hollinger J. O. Bone formation with use of rhBMP-2 (recombinant human bone morphogenetic protein-2). J Bone Joint Surg Am. 79:1997;1778-1790.
114. Sciadini M. F., Dawson J. M., Johnson K. D. Evaluation of bovine-derived bone protein with a natural coral carrier as a bone-graft substitute in a canine segmental defect model. J Orthop Res. 15:1997;844-857.
115. Honda Y., Knutsen R., Strong D. D., Sampath T. K., Baylink D. J., Mohan S. Osteogenic protein-1 stimulates mRNA levels of BMP-6 and decreases mRNA levels of BMP-2 and -4 in human osteosarcoma cells. Calcif Tissue Int. 60:1997;297-301.
116. Laitinen M., Jortikka L., Halttunen T. Measurement of total and local bone morphogenetic protein concentration in bone tumours. Int Orthop. 21:1997;188-193.
117. Weber K. L., Bolander M. E., Rock M. G., Pritchard D., Sarkar G. Evidence for the upregulation of osteogenic protein-1 mRNA expression in musculoskeletal neoplasms. J Orthop Res. 16:1998;8-14.